Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-
positive chromosome deriving from a translocation between chromosomes 22 and 9. The …

Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR–
ABL kinase inhibitors such that newly diagnosed patients have minimal disease …

Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of
Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard …

Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph+)
chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that is characterized
by the presence of the fusion oncogene BCR-ABL that encodes the tyrosine kinase BCR …

Chronic myeloid leukemia (CML) is a cancer of blood cells driven by the BCR–ABL1
oncogenic protein tyrosine kinase, which is the product of a reciprocal chromosomal …

Chronic myeloid leukaemia (CML) was the first leukaemia associated with a unique genetic
abnormality, the Philadelphia chromosome. This results from a reciprocal translocation …

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder of pluripotent
hematopoietic stem/progenitor cells that has been paradigmatic to our understanding of the …

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the
overproduction of granulocytes, which leads to high white blood cell counts and …

The idea that within the bulk of leukemic cells there are immature progenitors which are
intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not …